Barchart Demo Center

Overview

Stocks

Stock Screeners

ETFs

Futures

Funds

Fund Screeners

Foreign Exchange

Sectors

News

Financial Calculators

Embedded Widgets

Portfolio

Screener

JSON Feeds

Symbol Overview

United States|Canada
English|French

Evelo Biosciences Inc

(NASDAQ: EVLO)
Add to Portfolio
-0.10 (-1.80%)
as of Nov 21, 2019

Last 5.45
Change -0.10 (-1.80%)
Open 5.47
Prev. Close 5.55
Today's Range
4.98
5.51
52wk Range
4.90
15.89
Volume 79,000
Avg Volume 34,385
Sector SIC-2834 Pharmaceutical Preparations

Perfomance Comparison

Name Today 3-Month 1-Year
EVLO -1.80% -30.93% -39.44%
DJIA -0.20% +2.15% +13.50%
S&P 500 -0.16% +3.12% +17.12%

Key Statistics

Annual EPS -2.45
Dividend Yield 0.00%
P/E Ratio N/A
Market Capitalization, $K 180,960
Weighted Alpha -56.50
Standard Deviation -0.66
Profit Margin N/A
Beta -0.13

Growth Rates

YTD -58.11%
1-Year -39.51%

Opinion

Sell Hold Buy

Recent Headlines

Evelo Biosciences to Present at the Stifel 2019

GlobeNewswire via COMTEX - Wed Nov 13, 08:01AM EST
Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting biologics, today announced that management will present a corporate overview at the S(full story)
EVLO: 5.45 (-0.10)

Flagship Pioneering Appoints Prakash Raman, Ph.D. as

PR Newswire via COMTEX - Tue Nov 12, 08:00AM EST
Flagship Pioneering, a unique life sciences innovation enterprise, today announced the appointment of Prakash Raman, Ph.D. to the post of Senior Partner and the newly created role of Chief Business Development Officer. Dr. Raman m(full story)
NVS: 90.53 (unch), AXLA: 3.35 (-0.21), DNLI: 16.98 (+0.33), EVLO: 5.45 (-0.10), KLDO: 7.33 (-0.03), MRNA: 20.20 (+0.02), RUBY: 7.81 (-0.14)

Evelo Biosciences to Present Preclinical Data from its

GlobeNewswire via COMTEX - Fri Nov 08, 07:00AM EST
Evelo Biosciences (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting biologics, today announced that preclinical data from its oncology program, EDP1503, will b(full story)
EVLO: 5.45 (-0.10)

Evelo Biosciences Reports Further Positive EDP1815

GlobeNewswire via COMTEX - Tue Nov 05, 07:01AM EST
--EDP1815 was Well Tolerated with No Overall Difference Reported from Placebo--(full story)
EVLO: 5.45 (-0.10)

Evelo Biosciences Announces Further Positive Interim

GlobeNewswire via COMTEX - Tue Nov 05, 07:00AM EST
--EDP1815 was Well Tolerated with No Overall Difference Reported from Placebo--(full story)
EVLO: 5.45 (-0.10)